PART B QUESTIONS
Has the nature of the business problem from the perspectives of its main stakeholders changed for Gilead? If so, in what way(s)?
Does the increase in cure rate justify the additional cost?
Has the company been successful in addressing the business problem identified in part (A) of this case?
How should success be measured moving forward?
**THIS IS A CLASS DISCUSSION NO NEED FOR FRONT PAGE – PLEASE ANSWER IN ESSAY FORM NOT QUESTION ANSWER**
